Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Jul 9;74(1):104-132.
doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28.

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Craig T January, L Samuel Wann, Hugh Calkins, Lin Y Chen, Joaquin E Cigarroa, Joseph C Cleveland Jr, Patrick T Ellinor, Michael D Ezekowitz, Michael E Field, Karen L Furie, Paul A Heidenreich, Katherine T Murray, Julie B Shea, Cynthia M Tracy, Clyde W Yancy
Free article
Practice Guideline

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Craig T January et al. J Am Coll Cardiol. .
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Coll Cardiol. 2019 Jul 30;74(4):599. doi: 10.1016/j.jacc.2019.06.034. J Am Coll Cardiol. 2019. PMID: 31345442 No abstract available.
No abstract available

Keywords: ACC/AHA Clinical Practice Guidelines; acute coronary syndrome; anticoagulants; anticoagulation agents; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; cardioversion; coronary artery disease; coronary heart disease; dabigatran; edoxaban; focused update; hypertension; idarucizumab; myocardial infarction; obesity; percutaneous coronary intervention; risk factors; rivaroxaban; sleep apnea; stents; stroke; thromboembolism; warfarin.

PubMed Disclaimer

Publication types

MeSH terms